1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.

2. Reaven GM. Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000: 604-615.

3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.

4. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabet Rev 1997; 5:177-269.

5. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299:853-855.

6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999; 281:2005-2012.

7. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281-303.

8. Evans JL, Rushakoff RJ. Oral Pharmacological Agents for Type 2 Diabetes: Sulfonylureas, Meglitinides, Metformin, Thiazolidinediones, a-Glucosidase Inhibitors, and Emerging Approaches. In: Degroot L, Goldfine ID, Rushakoff RJ, editors. Endotext.com: Diabetes and Carbohydrate Metabolism. http://www.medtext.com:MDtext.com, 2002.

9. Fuhr JP, He H, Goldfarb N, Nash DB. Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. Dis Manag 2005; 8:265-275.

10. Altman SH, Parks-Thomas C. Controlling spending for prescription drugs. N Engl J Med 2002; 346:855-856.

11. Dham S, Shah V, Hirsch S, Banerji MA. The role of complementary and alternative medicine in diabetes. Curr Diab Rep 2006; 6:251-258.

12. Cicero AF, Derosa G, Gaddi A. What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. Acta Diabetol 2004; 41:91-98.

13. Saxena A, Vikram NK. Role of selected Indian plants in management of type 2 diabetes: a review. J Altern Complement Med 2004; 10:369-378.

14. Shekelle PG, Hardy M, Morton SC et al. Are Ayurvedic herbs for diabetes effective? J Fam Pract 2005; 54:876-886.

15. Andrade-Cetto A, Heinrich M. Mexican plants with hypoglycemic effect used in the treatment of diabetes. J Ethnopharmacol 2005; 99:325-348.

16. Johnson L, Strich H, Taylor A et al. Use of herbal remedies by diabetic Hispanic women in the southwestern United States. Phytother Res 2006; 20:250-255.

17. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc (Wash ) 2002; 42:217-226.

18. Berman BM, Swyers JP, Kaczmarczyk J. Complementary and alternative medicine: herbal therapies for diabetes. J Assoc Acad Minor Phys 1999; 10:10-14.

19. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 2002; 81:81-100.

20. Murray MT, Pizzorno JE. Botanical medicine ¿ a modern perspective. Textbook of Natural Medicine. Edinburgh: Churchill Livingstone, 1999.

21. AACE Nutrition Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 2003; 9:417-470.

22. Fontanarosa PB, Rennie D, DeAngelis CD. The need for regulation of dietary supplements-lessons from ephedra. J Am Med Assoc 2003; 289:1568-1570.

23. Kinsel JF, Straus SE. Complementary and alternative therpaeutics: rigorous research is needed to support claims. Annu Rev Pharmacol Toxicol 2003; 43:463-484.

24. Wolfe SM. Ephedra--scientific evidence versus money/politics. Science 2003; 300(5618):437.

25. Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138:468-471.

26. Shekelle PG, Hardy ML, Morton SC et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. J Am Med Assoc 2003; 289:1537-1545.

27. Yeh GY, Eisenberg DM, Davis RB, Phillips RS. Use of complementary and alternative medicine among persons with diabetes mellitus: results of a national survey. Am J Public Health 2002; 92:1648-1652.

28. Kim C, Kwok YS. Navajo use of native healers. Arch Intern Med 1998; 158:2245-2249.

29. Mull DS, Nguyen N, Mull JD. Vietnamese diabetic patients and their physicians: what ethnography can teach us. West J Med 2001; 175:307-311.

30. Noel PH, Pugh JA, Larme AC, Marsh G. The use of traditional plant medicines for non-insulin dependent diabetes mellitus in South Texas. Phytother Res 2003; 11:512-517.

31. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. J Am Med Assoc 1998; 280:1569-1575.

32. American Diabetes Association. Unproven therapies. Diabetes Care 2003; 26 (Suppl 1):S142.

33. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26:1277-1294.

34. Dey L, Attele AS, Yuan CS. Alternative therapies for type 2 diabetes. Altern Med Rev 2002; 7:45-58.

35. Evans JL, Maddux BA, Goldfine ID. Antioxidants in diabetic complications and insulin resistance. In: Raz I, Skyler JS, Shafrir E, editors. Diabetes: From Research to Diagnosis and Treatment. London: Martin Dunitz, 2003: 479-496.

36. Antioxidants in Diabetes Management. 1st ed. New York: Marcel Dekker, 2000.

37. Ha T, Lean MEJ. Diet and lifestyle modification in the management of non-insulin-dependent diabetes mellitus. In: Pickup JC, Williams G, editors. Textbook of Diabetes. Oxford: Blackwell Science, 1997: 1-18.

38. Jenkins DJA, Jenkins AL, Kendall CWC. Dietary therapy in type 2 diabetes mellitus: spreading the nutrient load. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2002: 757-765.

39. Costacou T, Mayer-Davis EJ. Nutrition and prevention of type 2 diabetes. Annu Rev Nutr 2003; 23:147-170.

40. Youngren JF. Exercise and the regulation of blood glucose. In: Degroot L, Goldfine ID, Rushakoff RJ, editors. Endotext.org: Diabetes and Carbohydrate Metabolism. Internet-based: http://www.mdtext.com/,3 A.D.: http://www.mdtext.com/diabetes/diabetes14/diabetesframe14.htm.

41. Watts NB, Spanheimer RG, DiGirolamo M et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1990; 150:803-806.

42. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147:1749-1753.

43. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16:397-415.

44. Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes--2006: a position statement of the American Diabetes Association. Diabetes Care 2006; 29:2140-2157.

45. Diabetes Medical Guidelines Task Force. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8 (Suppl.1):40-82.

46. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000; 342:1392-1398.

47. Vuksan V, Sievenpiper JL, Owen R et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000; 23:9-14.

48. Frape DL, Jones AM. Chronic and postprandial responses of plasma insulin, glucose and lipids in volunteers given dietary fibre supplements. Br J Nutr 1995; 73:733-751.

49. Lakhdar A, Farish E, McLaren EH. Fibre and patients with diabetes. Br Med J 1988; 296:1471.

50. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet 2006; 367:320-326.

51. Lichtenstein AH, Appel LJ, Brands M et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114:82-96.

52. Stanner SA, Hughes J, Kelly CN, Buttriss J. A review of the epidemiological evidence for the 'antioxidant hypothesis'. Public Health Nutr 2004; 7:407-422.

53. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. J Am Med Assoc 2005; 294:97-104.

54. Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR, Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004; 80:1194-1200.

55. Liu S, Lee IM, Song Y et al. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. Diabetes 2006; 55:2856-2862.

56. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. J Am Med Assoc 2005; 293:1338-1347.

57. Boshtam M, Rafiei M, Golshadi ID, Ani M, Shirani Z, Rostamshirazi M. Long term effects of oral vitamin E supplement in type II diabetic patients. Int J Vitam Nutr Res 2005; 75:341-346.

58. Keys A. Mediterranean diet and public health: personal reflections. Am J Clin Nutr 1995; 619 (6 Suppl):1321S-1323S.

59. Curtis BM, O'Keefe JH, Jr. Understanding the Mediterranean diet. Could this be the new "gold standard" for heart disease prevention? Postgrad Med 2002; 112:35.

60. de LM, Salen P. The Mediterranean-style diet for the prevention of cardiovascular diseases. Public Health Nutr 2006; 9:118-123.

61. Willett WC. The Mediterranean diet: science and practice. Public Health Nutr 2006; 9:105-110.

62. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev 2006; 64:S27-S47.

63. Trichopoulou A. Mediterranean diet: the past and the present. Nutr Metab Cardiovasc Dis 2001; 11 (4 Suppl):1-4.

64. Schroder H. Protective mechanisms of the Mediterranean diet in obesity and type 2 diabetes. J Nutr Biochem 2006; Epub ahead of print.

65. Estruch R, Martinez-Gonzalez MA, Corella D et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006; 145:1-11.

66. Biesalski HK. Diabetes preventive components in the Mediterranean diet. Eur J Nutr 2004; 43 Suppl 1:I/26-I/30.

67. Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. The epidemiology of type 2 diabetes mellitus in Greek adults: the ATTICA study. Diabet Med 2005; 22:1581-1588.

68. Hung HC, Joshipura KJ, Jiang R et al. Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 2004; 96:1577-1584.

69. Fraga CG. Cocoa, diabetes, and hypertension: should we eat more chocolate? Am J Clin Nutr 2005; 81:541-542.

70. Fisher ND, Hughes M, Gerhard-Herman M, Hollenberg NK. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 2003; 21:2281-2286.

71. Fisher ND, Hollenberg NK. Flavanols for cardiovascular health: the science behind the sweetness. J Hypertens 2005; 23:1453-1459.

72. Rein D, Lotito S, Holt RR, Keen CL, Schmitz HH, Fraga CG. Epicatechin in human plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status. J Nutr 2000; 130:2109S-2114S.

73. Vlachopoulos C, Aznaouridis K, Alexopoulos N, Economou E, Andreadou I, Stefanadis C. Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens 2005; 18:785-791.

74. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 2005; 81:611-614.

75. Grassi D, Necozione S, Lippi C et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005; 46:398-405.

76. Griggs B. Green Pharmacy. A history of herbal medicine. 1st ed. London: Robert Hale, 1981.

77. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.

78. Witters LA. The blooming of the French lilac. J Clin Invest 2001; 108:1105-1107.

79. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6:89-131.

80. Oubre AY, Carlson TJ, King SR, Reaven GM. From plant to patient: An ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia 1997; 40:614-617.

81. Ackerknecht EH. A Short History of Medicine (revised edition). Baltimore: Johns Hopkins Unversity Press, 1982.

82. Bailey CJ, Day C. Traditional plant medicine as treatments for diabetes. Diabetes Care 1989; 12:553-564.

83. Marles RJ, Farnsworth NR. Plants as sources of antidiabetic agents. Economic and Medical Plant Research 1993; 6:149-187.

84. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents. Phytomed 1995; 2:137-189.

85. Haddad PS, Depot M, Settaf A, Cherrah Y. Use of antidiabetic plants in Morocco and Quebec. Diabetes Care 2001; 24:608-609.

86. Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK. Antidiabetic agents from medicinal plants. Curr Med Chem 2006; 13:1203-1218.

87. Kusano S, Abe H. Antidiabetic activity of white skinned sweet potato (Ipomoea batatas L.) in obese Zucker fatty rats. Biol Pharm Bull 2000; 23:23-26.

88. Kusano S, Abe H, Tamura H. Isolation of antidiabetic components from white-skinned sweet potato (Ipomoea batatas L.). Biosci Biotechnol Biochem 2001; 65:109-114.

89. Ludvik BH, Mahdjoobian K, Waldhaeusl W et al. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. Diabetes Care 2002; 25:239-240.

90. Ludvik B, Waldhausl W, Prager R, Kautzky-Willer A, Pacini G. Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients. Metabolism 2003; 52:875-880.

91. Ludvik B, Neuffer B, Pacini G. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. Diabetes Care 2004; 27:436-440.

92. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29:2137-2139.

93. Anonymous. PDR for Herbal Medicines. 1st ed ed. Montvale, NJ: Medical Economics Co, 1998.

94. Brasch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. Altern Med Rev 2003; 8:20-27.

95. Sauvaire Y, Petit P, Broca C et al. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes 1998; 47:206-210.

96. Broca C, Manteghetti M, Gross R et al. 4-Hydroxyisoleucine: effects of synthetic and natural analogues on insulin secretion. Eur J Pharmacol 2000; 390:339-345.

97. Broca C, Gross R, Petit P et al. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol 1999; 277:E617-E623.

98. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr 1988; 42:51-54.

99. Sharma RD, Sarkar A, Hazra DK. Use of fenugreek seed powder in the management of non-inslin dependent diabetes mellitus. Nutr Res 1996; 16:1331-1339.

100. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India 2001; 49:1057-1061.

101. Kochhar A, Nagi M. Effect of supplementation of traditional medicinal plants on blood glucose in non-insulin-dependent diabetics: a pilot study. J Med Food 2005; 8:545-549.

102. Flammang AM, Cifone MA, Erexson GL, Stankowski LF, Jr. Genotoxicity testing of a fenugreek extract. Food Chem Toxicol 2004; 42:1769-1775.

103. Khan A, Bryden NA, Polansky MM, Anderson RA. Insulin potentiating factor and chromium content of selected foods and spices. Biol Trace Element Res 1990; 24:183-188.

104. Berrio LF, Polansky MM, Anderson RA. Insulin activity: stimulatory effects of cinnamon and brewer's yeast as influenced by albumin. Horm Res 1992; 37:225-229.

105. Evans JL, Jallal B. Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Exp Opin Invest Drugs 1999; 8:139-160.

106. Imparl-Radosevich J, Deas S, Polansky MM et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Horm Res 1998; 50:177-182.

107. Khan A, Safdar M, li Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003; 26:3215-3218.

108. Mang B, Wolters M, Schmitt B et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest 2006; 36:340-344.

109. Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig WK, van Loon LJ. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr 2006; 136:977-980.

110. Nag B, Medicherla S, Sharma SD. Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes. US Patent 2002; 6,391,854:1-14.

111. Krawinkel MB, Keding GB. Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia. Nutr Rev 2006; 64:331-337.

112. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60:356-359.

113. Roman-Ramos R, Flores-Saenz JL, Alarcon-Aguilar FJ. Anti-hyperglycemic effect of some edible plants. J Ethnopharmacol 1995; 48:25-32.

114. El Kossori RL, Villaume C, El Boustani E, Sauvaire Y, Mejean L. Composition of pulp, skin and seeds of prickly pears fruit (Opuntia ficus indica sp.). Plant Foods Hum Nutr 1998; 52:263-270.

115. Frati AC, Gordillo BE, Altamirano P, Ariza CR, Cortes-Franco R, Chavez-Negrete A. Acute hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care 1990; 13:455-456.

116. Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care 1988; 11:63-66.

117. Azad Khan AK, Akhtar S, Mahtab H. Coccinia indica in the treatment of patients with diabetes mellitus. Bangladesh Med Res Counc Bull 1979; 5:60-66.

118. Xie JT, Mchendale S, Yuan CS. Ginseng and diabetes. Am J Chin Med 2005; 33:397-404.

119. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol 1999; 55:567-575.

120. Sievenpiper JL, Arnason JT, Vidgen E, Leiter LA, Vuksan V. A systematic quantitative analysis of the literature of the high variability in ginseng (Panax spp.): should ginseng be trusted in diabetes? Diabetes Care 2004; 27:839-840.

121. Vuksan V, Sievenpiper JL. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. Nutr Metab Cardiovasc Dis 2005; 15:149-160.

122. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995; 18:1373-1375.

123. Vuksan V, Sievenpiper JL, Koo VY et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 2000; 160:1009-1013.

124. Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical effectiveness. Br J Gen Pract 1999; 49:823-828.

125. Al Rowais NA. Herbal medicine in the treatment of diabetes mellitus. Saudi Med J 2002; 23:1327-1331.

126. Ghannam N, Kingston M, Al Meshaal IA, Tariq M, Parman NS, Woodhouse N. The antidiabetic activity of aloes: preliminary clinical and experimental observations. Horm Res 1986; 24:288-294.

127. Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: I. Clinical trial in new cases of diabetes mellitus. Phytomed 1996; 3:241-243.

128. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomed 1996; 3:245-248.

129. Vuksan V, Jenkins DJA, Spadafora P et al. Konjac-Mannan (Glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes - A randomized controlled metabolic trial. Diabetes Care 1999; 22:913-919.

130. Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders: a review. Nutr J 2002; 1:4.

131. Borek C. Garlic reduces dementia and heart-disease risk. J Nutr 2006; 136:810S-812S.

132. Budoff M. Aged garlic extract retards progression of coronary artery calcification. J Nutr 2006; 136:741S-744S.

133. Ahmad MS, Ahmed N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr 2006; 136:796S-799S.

134. Kendler BS. Garlic (Allium sativum) and onion (Allium cepa): a review of their relationship to cardiovascular disease. Prev Med 1987; 16:670-685.

135. Keys A. Wine, garlic, and CHD in seven countries. Lancet 1980; 1:145-146.

136. Kris-Etherton PM, Etherton TD, Carlson J, Gardner C. Recent discoveries in inclusive food-based approaches and dietary patterns for reduction in risk for cardiovascular disease. Curr Opin Lipidol 2002; 13:397-407.

137. Ashraf R, Aamir K, Shaikh AR, Ahmed T. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus. J Ayub Med Coll Abbottabad 2005; 17:60-64.

138. Covington MB. Traditional Chinese medicine in the treament of diabetes. Diabetes Spectrum 2001; 14:154-159.

139. Jia W, Gao W, Tang L. Antidiabetic herbal drugs officially approved in China. Phytother Res 2003; 17:1127-1134.

140. Liu JP, Zhang M, Wang WY, Grimsgaard S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database Syst Rev 2004; Issue 3:CD003642.

141. Li WL, Zheng HC, Bukuru J, De KN. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004; 92:1-21.

142. Jia W, Gao WY, Xiao PG. Antidiabetic drugs of plant origin used in China: compositions, pharmacology, and hypoglycemic mechanisms. Zhongguo Zhong Yao Za Zhi 2003; 28:108-113.

143. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-820.

144. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2004; 7:1040-1052.

145. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and ¿ dysfunction? Diabetes 2003; 52:1-8.

146. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23:599-622.

147. Evans JL, Youngren JF, Goldfine ID. Effective treatments for insulin resistance: trim the fat and douse the fire. Trends Endocrinol Metab 2004; 15:425-431.

148. Henriksen EJ. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Biol Med 2006; 40:3-12.

149. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19:227-250.

150. Packer L, Witt EH, Tritschler HJ. Antioxidant properties and clinical applications of alpha-lipoic acid and dihydrolipoic acid. In: Cadenas E, Packer L, editors. Handbook of Antioxidants. New York: Dekker, 1998: 545-591.

151. Fuchs J, Packer L, Zimmer G. Lipoic Acid in Health and Disease. 1st ed. New York: Marcel Dekker, 1997.

152. Reed LJ, DeBusk BG, Gunsalus IC, Hornberger JrCS. Crystalline a-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science 1951; 114:93-94.

153. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997; 29:315-331.

154. Biewenga GP, Haenen GR, Bast A. The role of lipoic acid in the treatment of diabetic polyneuropathy. Drug Metab Rev 1997; 29:1025-1054.

155. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997; 46 Suppl 2:S62-S66.

156. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999; 107:421-430.

157. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21:114-121.

158. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004; 3:173-189.

159. Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care 2006; 12 (9 Suppl):S269-S278.

160. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29:2365-2370.

161. Doggrell SA. Alpha-lipoic acid, an anti-obesity agent? Expert Opin Investig Drugs 2004; 13:1641-1643.

162. Jacob S, Henriksen EJ, Schiemann AL et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittel-Forschung 1995; 45:872-874.

163. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996; 104:284-288.

164. Evans JL, Goldfine ID. a-Lipoic acid: a multi-functional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Therap 2000; 2:401-413.

165. Jacob S, Rett K, Henriksen EJ, Haring HU. Thioctic acid: effects on insulin sensitivity and glucose metabolism. BioFactors 1999; 10:169-174.

166. Jacob S, Ruus P, Hermann R et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type 2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999; 27:309-314.

167. Konrad T, Vicini P, Kusterer K et al. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999; 22:280-287.

168. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of a-lipoic acid. Endocr Pract 2002; 8:29-35.

169. Pjodkowaki RA, Grotz VL, Mudalar S, Henry RR. The effects of alpha-lipoic acid on glucose homeostasis in type 2 diabetes. J Invest Med 50, 71A-71A (Abstract 382). 2002. Ref Type: Abstract

170. Rudich A, Tirosh A, Potashnik R, Khamaisi M, Bashan N. Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes. Diabetologia 1999; 42:949-957.

171. Maddux BA, See W, Lawrence JC, Jr., Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of a-lipoic acid. Diabetes 2001; 50:404-410.

172. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001; 15:2423-2432.

173. Birnbaum MJ. Turning down insulin signaling. J Clin Invest 2001; 108:655-659.

174. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.

175. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kB activation in late diabetic complications. BioFactors 1999; 10:157-167.

176. Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50:2792-2808.

177. Bierhaus A, Chevion S, Chevion M et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46:1481-1490.

178. Packer L. alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metab Rev 1998; 30:245-275.

179. Hofmann MA, Schiekofer S, Kanitz M et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998; 21:1310-1316.

180. Hofmann MA, Schiekofer S, Isermann B et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999; 42:222-232.

181. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51:1319-1336.

182. Rossi A, Kapahi P, Natoli G et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403:103-108.

183. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKb. Science 2001; 293:1673-1677.

184. Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108:437-446.

185. Hundal RS, Petersen KF, Mayerson AB et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109(10):1321-1326.

186. Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. J Parenter Enteral Nutr 1986; 10:227-238.

187. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.

188. Fried R, Merrell WC. The Arginine Solution. 1 ed. New York: Warner Books, 1999.

189. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.

190. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994; 372:546-548.

191. Reid MB. Role of nitric oxide in skeletal muscle: synthesis, distribution and functional importance. Acta Physiol Scand 1998; 162:401-409.

192. Luscher TF, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118 (Suppl):S81-S90.

193. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92:652-662.

194. Tschudi MR, Barton M, Bersinger NA et al. Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest 1996; 98:899-905.

195. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998; 31:1047-1060.

196. Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998; 14:241-249.

197. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 2002; 55:250-260.

198. Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 2001; 41:79-99.

199. Cooke JP, Zimmer J. The Cardiovascular Cure. How to Strengthen Your Self-Defense Against Heart Attack and Stroke. 1st ed. New York: Broadway, 2002.

200. Preli RB, Klein KP, Herrington DM. Vascular effects of dietary L-arginine supplementation. Atherosclerosis 2002; 162:1-15.

201. Lekakis JP, Papathanassiou S, Papaioannou TG et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002; 86:317-323.

202. Maxwell AJ, Anderson B, Zapien MP, Cooke JP. Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc Drugs Ther 2000; 14:309-316.

203. Clarkson P, Adams MR, Powe AJ et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97:1989-1994.

204. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997; 129:261-269.

205. Lerman A, Burnett JC, Jr., Higano ST, McKinley LJ, Holmes DR, Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97:2123-2128.

206. Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 2002; 21:422-427.

207. Mehta S, Stewart DJ, Levy RD. The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest 1996; 109:1550-1555.

208. Facchinetti F, Longo M, Piccinini F, Neri I, Volpe A. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Investig 1999; 6:202-207.

209. Kelly BS, Alexander JW, Dreyer D et al. Oral arginine improves blood pressure in renal transplant and hemodialysis patients. J Parenter Enteral Nutr 2001; 25:194-202.

210. Setoguchi S, Hirooka Y, Eshima K, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J Cardiovasc Pharmacol 2002; 39:363-368.

211. Blum A, Hathaway L, Mincemoyer R et al. Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women. J Am Coll Cardiol 2000; 35:271-276.

212. Blum A, Hathaway L, Mincemoyer R et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101:2160-2164.

213. Knekt P, Ritz J, Pereira MA et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr 2004; 80:1508-1520.

214. Osganian SK, Stampfer MJ, Rimm E et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol 2003; 42:246-252.

215. Wannamethee SG, Lowe GD, Rumley A, Bruckdorfer KR, Whincup PH. Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr 2006; 83:567-574.

216. Boekholdt SM, Meuwese MC, Day NE et al. Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. Br J Nutr 2006; 96:516-522.

217. Levine GN, Keaney JF, Jr., Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332(8):512-521.

218. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-844.

219. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000; 47:457-464.

220. Baron AD, Quon MJ. Insulin action and endothelial function. In: Reaven GM, Laws A, editors. Insulin Resistance: The Metabolic Syndrome X. Totowa: Humana Press, 1999: 247-263.

221. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22:36-52.

222. Perticone F, Ceravolo R, Candigliota M et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50:159-165.

223. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998; 31:552-557.

224. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97:22-28.

225. Lekakis JP, Anastasiou EA, Papamichael CM et al. Short-term oral ascorbic acid improves endothelium-dependent vasodilatation in women with a history of gestational diabetes mellitus. Diabetes Care 2000; 23:1432-1434.

226. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Jr., Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93:1107-1113.

227. Gokce N, Keaney JF, Jr., Frei B et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999; 99(25):3234-3240.

228. Hirai N, Kawano H, Hirashima O et al. Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C. Am J Physiol 2000; 279:H1172-H1178.

229. Hirashima O, Kawano H, Motoyama T et al. Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. J Am Coll Cardiol 2000; 35:1860-1866.

230. Antoniades C, Tousoulis D, Tountas C et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet Med 2004; 21:552-558.

231. Anderson RA, Evans LM, Ellis GR et al. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet Med 2006; 23:258-264.

232. Chen H, Karne RJ, Hall G et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol 2006; 290:H137-H145.

233. Bonakdar RA, Guarneri E. Coenzyme Q₁₀. Am Fam Physician 2005; 72:1065-1070.

234. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q₁₀ on blood pressure and insullin resistance in hypertensive patients with coronary heart disease. J Hum Hypertens 1999; 13:203-208.

235. Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ₁₀-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33:226-229.

236. Colquhoun DM, Jackson R, Walters M et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q₁₀ levels and left ventricular function in humans. Eur J Clin Invest 2005; 35:251-258.

237. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3:463-524.

238. Paolisso G, Esposito R, D'Alessio MA, Barbieri M. Primary and secondary prevention of atherosclerosis: is there a role for antioxidants? Diabetes Metab 1999; 25(4):298-306.

239. Devaraj S, Jialal I. Antioxidants and vitamins to reduce cardiovascular disease. Curr Atheroscler Rep 2000; 2:342-351.

240. Jialal I, Traber M, Devaraj S. Is there a vitamin E paradox? Curr Opin Lipidol 2001; 12:49-53.

241. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154-160.

242. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 2000; 102:191-196.

243. Bursell SE, Clermont AC, Aiello LP et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22:1245-1251.

244. Gaede P, Poulsen HE, Parving HH, Pedersen O. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med 2001; 18:756-760.

245. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 2001; 73:1052-1057.

246. Caballero B. Vitamin E improves the action of insulin. Nutrit Rev 1993; 51:339-340.

247. Paolisso G, D'Amore A, Galzerano D et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993; 16:1433-1437.

248. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertension 1998; 6:895-906.

249. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacological doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutrit 1993; 57:650-656.

250. Paolisso G, Di Maro G, Galzerano D et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr 1994; 59:1291-1296.

251. Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G. Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. Hypertension 1999; 34:1002-1006.

252. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26:3264-3272.

253. Czernichow S, Couthouis A, Bertrais S et al. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr 2006; 84:395-399.

254. Economides PA, Khaodhiar L, Caselli A et al. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 2005; 54:204-211.

255. McSorley PT, Bell PM, Young IS et al. Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with Type 2 diabetes: effect of vitamin E in a randomized double-blind, controlled clinical trial. Diabet Med 2005; 22:703-710.

256. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998; 82:18U-23U.

257. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162:1568-1576.

258. Mccarty MF. Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications. Med Hypotheses 1997; 49:143-152.

259. Mertz W. Chromium research from a distance: from 1959 to 1980. J Am Coll Nutr 1998; 17:544-547.

260. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet Med 2000; 17:684-685.

261. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977; 30:531-538.

262. Mooradian AD, Failla M, Hoogwerf B, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. Diabetes Care 1994; 17:464-479.

263. Trumbo PR, Ellwood KC. Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration. Nutr Rev 2006; 64:357-363.

264. Kleefstra N, Houweling ST, Jansman FG et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006; 29:521-525.

265. Martin J, Wang ZQ, Zhang XH et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006; 29:1826-1832.

266. Racek J, Trefil L, Rajdl D, Mudrova V, Hunter D, Senft V. Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res 2006; 109:215-230.

267. Anderson RA. Chromium in the prevention and control of diabetes. Diabetes Metab 2000; 26:22-27.

268. Lukaski HC. Chromium as a supplement. Annu Rev Nutr 1999; 19:279-302.

269. Lamson DS, Plaza SM. The safety and efficacy of high-dose chromium. Altern Med Rev 2002; 7:218-235.

270. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 2002; 76:148-155.

271. Anderson RA, Cheng N, Bryden NA, Polansky MM, Chi J, Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46:1786-1791.

272. Uusitupa MI, Mykkanen L, Siitonen O et al. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. Br J Nutr 1992; 68:209-216.

273. Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc 1997; 29:992-998.

274. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27:2741-2751.

275. Juturu V, Komorowski JR. Chromium supplements, glucose, and insulin responses. Am J Clin Nutr 2003; 78:190-193.

276. Anderson RA, Polansky MM, Bryden NA. Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Biol Trace Elem Res 2004; 101:211-218.

277. DiSilvestro RA, Dy E. Acute absorption comparison of commercially available chromium supplements and one new supplement. Biol Trace Elem Res. In press.

278. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 2006; 136:415-420.

279. Byon JCH, Kusari AB, Kusari J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem 1998; 182:101-108.

280. Elchebly M, Payette P, Michaliszyn E et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 283:1544-1548.

281. Klaman LD, Boss O, Peroni OD et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000; 20:5479-5489.

282. Goldstein BJ. Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity, and related states of insulin resistance. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1:265-275.

283. Ramachandran C, Kennedy BP. Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity. Curr Top Med Chem 2003; 3:749-757.

284. Malamas MS, Sredy J, Gunawan I et al. New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem 2000; 43:995-1010.

285. Cheon HG, Kim SM, Yang SD, Ha JD, Choi JK. Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur J Pharmacol 2004; 485:333-339.

286. Liu G, Szczepankiewicz BG, Pei Z et al. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2003; 46:2093-2103.

287. Wang H, Kruszewski A, Brautigan DL. Cellular chromium enhances activation of insulin receptor kinase. Biochemistry 2005; 44:8167-8175.

288. Pender C, Youngren JF, Manchem VP et al. Regulation of insulin receptor function by a small molecule insulin receptor activator. J Biol Chem 2002; epub 9/3/2002.

289. Li M, Youngren JF, Dunaif A et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of sering kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002; 87:4088-4093.

290. Laires MJ, Monteiro CP, Bicho M. Role of cellular magnesium in health and human disease. Front Biosci 2004; 9:262-276.

291. Anonymous. PDR for nutritional supplements. 1st ed ed. Montvale, NJ: Medical Economics Co, 2001.

292. Yokota K. Diabetes mellitus and magnesium. Clin Calcium 2005; 15:203-212.

293. Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes Res 2004; 17:126-136.

294. Barbagallo M, Dominguez LJ, Galioto A et al. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med 2003; 24:39-52.

295. Tosiello L. Hypomagnesemia and diabetes mellitus: A review of clinical implications. Arch Intern Med 1996; 156:1143-1148.

296. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem 2002; 238:163-179.

297. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens 1997; 10:346-355.

298. Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001; 94:1195-1201.

299. Lopez-Ridaura R, Willett WC, Rimm EB et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004; 27:134-140.

300. Murakami K, Okubo H, Sasaki S. Effect of dietary factors on incidence of type 2 diabetes: a systematic review of cohort studies. J Nutr Sci Vitaminol (Tokyo) 2005; 51:292-310.

301. Song Y, Manson JE, Buring JE, Liu S. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004; 27:59-65.

302. Ma B, Lawson AB, Liese AD, Bell RA, Mayer-Davis EJ. Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dose-dependent association. Am J Epidemiol 2006; 164:449-458.

303. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman RN, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21:1024-1029.

304. de Valk HW. Magnesium in diabetes mellitus. Neth J Med 1999; 54:139-146.

305. Huerta MG, Roemmich JN, Kington ML et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care 2005; 28(5):1175-1181.

306. Sjogren A, Floren CH, Nilsson A. Oral administration of magnesium hydroxide to subjects with insulin-dependent diabetes mellitus: effects on magnesium and potassium levels and on insulin requirements. Magnesium 1988; 7(3):117-122.

307. Paolisso G, Sgambato S, Pizza G, Passariello N, Varricchio M, D'Onofrio F. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care 1989; 12:265-269.

308. Paolisso G, Passariello N, Pizza G et al. Dietary magnesium supplements improve ¿ response to glucose and arginine in elderly non-insulin dependent diabetic subjects. Acta Endocrinol 1989; 121:16-20.

309. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003; 26:1147-1152.

310. Yokota K, Kato M, Lister F et al. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. J Am Coll Nutr 2004; 23:506S-509S.

311. Faure P, Roussel A, Coudray C, Richard MJ, Halimi S, Favier A. Zinc and insulin sensitivity. Biol Trace Elem Res 1992; 32:305-310.

312. Arquilla ER, Packer S, Tarmas W, Miyamoto S. The effect of zinc on insulin metabolism. Endocrinology 1978; 103:1440-1449.

313. Haase H, Maret W. Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals 2005; 18:333-338.

314. Salgueiro MJ, Krebs N, Zubillaga MB et al. Zinc and diabetes mellitus: is there a need of zinc supplementation in diabetes mellitus patients? Biol Trace Elem Res 2001; 81:215-228.

315. DiSilvestro RA. Zinc in relation to diabetes and oxidative disease. J Nutr 2000; 130 (5S Suppl):1509S-1511S.

316. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002; 33:337-349.

317. Al-Maroof RA, Al-Sharbatti SS. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J 2006; 27:344-350.

318. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005; 28:2458-2464.

319. Farvid MS, Siassi F, Jalali M, Hosseini M, Saadat N. The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. Diabetes Res Clin Pract 2004; 65:21-28.

320. Anonymous. Vanadium. In: Hendler SS, Rorvik D, Fleming T, Deutsch M, Wyble C, editors. PDR for nutritional supplements. Montvale, NJ: Medical Economics Co, 2001: 459-460.

321. Mehdi MZ, Pandey SK, Theberge JF, Srivastava AK. Insulin signal mimicry as a mechanism for the insulin-like effects of vanadium. Cell Biochem Biophys 2006; 44:73-81.

322. Srivastava AK, Mehdi MZ. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 2005; 22:2-13.

323. Posner BI, Faure R, Burgess JW et al. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 1994; 269:4596-4604.

324. Elberg G, He ZB, Li JP, Sekar N, Shechter Y. Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes. Diabetes 1997; 46:1684-1690.

325. Tsiani E, Fantus IG. Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrin Metabol 1997; 8:51-58.

326. Sekar N, Li JP, Shechter Y. Vanadium salts as insulin substitutes: Mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Crit Rev Biochem Molec Biol 1996; 31:339-359.

327. Heyliger CE, Tahiliani AG, McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 1985; 227:1474-1477.

328. Yale JF, Lachance D, Bevan AP, Vigeant C, Shaver A, Posner BI. Hypoglycemic effects of peroxovanadium compoundsin Sprague-Dawley and diabetic BB rats. Diabetes 1995; 44:1274-1279.

329. Yao J, Battell ML, McNeill JH. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction. Can J Physiol Pharmacol 1997; 75:83-90.

330. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1286-1294.

331. Verma S, Cam MC, McNeill JH. Nutritional factors that that favorably influence the glucose/insulin system: Vanadium. J Am Coll Nutr 1998; 17:11-18.

332. Goldfine AB, Simonson DC, Folli F, Patti E, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 1995; 153:217-231.

333. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab 1995; 80:3311-3320.

334. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996; 45:659-666.

335. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 95:2501-2509.

336. Boden G, Chen XH, Ruiz J, Vanrossum GDV, Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996; 45:1130-1135.

337. Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, Redondo JC. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2001; 86:1410-1417.

338. Thompson KH, Orvig C. Vanadium compounds in the treatment of diabetes. Met Ions Biol Syst 2004; 41:221-252.

339. Kofuji K, Qian CJ, Murata Y, Kawashima S. The controlled release of insulin-mimetic metal ions by the multifunction of chitosan. J Inorg Biochem 2005; 99:1329-1334.

340. Badmaev V, Prakash S, Majeed M. Vanadium: a review of its potential role in the fight against diabetes. J Altern Complement Med 1999; 5:273-291.

341. Hasenknopf B. Polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications. Front Biosci 2005; 10:275-287.

342. Sakurai H. Therapeutic potential of vanadium in treating diabetes mellitus. Clin Calcium 2005; 15:49-57.

343. Domingo JL. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. Biol Trace Elem Res 2002; 88:97-112.

344. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002; 100:1340-1346.

345. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277:8755-8758.

346. Hu FB, Bronner L, Willett WC et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. J Am Med Assoc 2002; 287:1815-1821.

347. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001; 161:2185-2192.

348. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids--a review. Nutr Metab Cardiovasc Dis 2000; 10:28-37.

349. Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr 2001; 131:1129-1132.

350. Evans JL, Lin JJ, Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARa, PPARg, and PPARd. Current Diabetes Reviews 2005; 1:299-307.

351. Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 2002; 13:155-164.

352. Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a mechanism to improve energy balance and insulin resistance. Br J Nutr 2000; 83 Suppl 1:S59-S66.

353. Xu HE, Lambert MH, Montana VG et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999; 3:397-403.

354. Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2:757-761.

355. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779-785.

356. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. Cardiovasc Drugs Ther 1997; 11:485-491.

357. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-455.

358. Kris-Etherton PM, Taylor DS, Yu-Poth S et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000; 71 (1 Suppl):179S-188S.

359. Roche HM. Unsaturated fatty acids. Proc Nutr Soc 1999; 58:397-401.

360. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8:105-110.

361. Friday KE, Childs MT, Tsunehara CH, Fujimoto WY, Bierman EL, Ensinck JW. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989; 12:276-281.

362. Vessby B, Boberg M. Dietary supplementation with n-3 fatty acids may impair glucose homeostasis in patients with non-insulin-dependent diabetes mellitus. J Intern Med 1990; 228:165-171.

363. Mcmanus RM, Jumpson J, Finegood DT, Clandinin MT, Ryan EA. A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type II diabetes. Diabetes Care 1996; 19:463-467.

364. Luo J, Rizkalla SW, Vidal H et al. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men: Results of a controlled study. Diabetes Care 1998; 21:717-724.

365. Prince MJ, Deeg MA. Do n-3 fatty acids improve glucose tolerance and lipemia in diabetics? Curr Opin Lipidol 1997; 8:7-11.

366. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000; 23:1407-1415.

367. Carpentier YA, Portois L, Malaisse WJ. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 2006; 83 (6 Suppl):1499S-1504S.

368. Mostad IL, Bjerve KS, Bjorgaas MR, Lydersen S, Grill V. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr 2006; 84:540-550.

369. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. Prog Lipid Res 2001; 40:283-298.

370. Ha YL, Grimm NK, Pariza MW. Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid. Carcinogenesis 1987; 8:1881-1887.

371. Ip C, Chin SF, Scimeca JA, Pariza MW. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res 1991; 51:6118-6124.

372. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr 2002; 22:505-531.

373. MacDonald HB. Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000; 19 (2 Suppl):111S-118S.

374. Moya-Camarena SY, Vanden Heuvel JP, Blanchard SG, Leesnitzer LA, Belury MA. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARa. J Lipid Res 1999; 40:1426-1433.

375. DeLany JP, West DB. Changes in body composition with conjugated linoleic acid. J Am Coll Nutr 2000; 19:487S-493S.

376. Ryder JW, Portocarrero CP, Song XM et al. Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 2001; 50:1149-1157.

377. Belury MA, Mahon A, Banni S. The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. J Nutr 2003; 133(1):257S-260S.

378. Salas-Salvado J, Marquez-Sandoval F, Bullo M. Conjugated linoleic acid intake in humans: a systematic review focusing on its effect on body composition, glucose, and lipid metabolism. Crit Rev Food Sci Nutr 2006; 46:479-488.

379. Brown JM, McIntosh MK. Conjugated linoleic acid in humans: regulation of adiposity and insulin sensitivity. J Nutr 2003; 133:3041-3046.

380. Bhattacharya A, Banu J, Rahman M, Causey J, Fernandes G. Biological effects of conjugated linoleic acids in health and disease. J Nutr Biochem 2006; April 28 (Epub ahead of print).

381. Wang YW, Jones PJ. Conjugated linoleic acid and obesity control: efficacy and mechanisms. Int J Obes Relat Metab Disord 2004; 28:941-955.

382. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans--metabolic effects. Lipids 2001; 36:773-781.

383. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat in healthy exercising humans. J Int Med Res 2001; 29:392-396.

384. Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000; 130:2943-2948.

385. Riserus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care 2002; 25:1516-1521.

386. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation 2002; 106:1925-1929.

387. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr 2004; 80:887-895.

388. Riserus U, Vessby B, Arner P, Zethelius B. Supplementation with trans10cis12-conjugated linoleic acid induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. Diabetologia 2004; 47:1016-1019.

389. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27:391-401.

390. Canter PH, Ernst E. Ginkgo biloba: a smart drug? A systematic review of controlled trials of the cognitive effects of ginkgo biloba extracts in healthy people. Psychopharmacol Bull 2002; 36:108-123.

391. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;CD003120.

392. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001; 41:600-611.